<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37378756</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Retrospective observational study on the use of acetyl-L-carnitine in ALS.</ArticleTitle><Pagination><StartPage>5344</StartPage><EndPage>5357</EndPage><MedlinePgn>5344-5357</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-023-11844-6</ELocationID><Abstract><AbstractText>ALCAR (Acetyl-L-carnitine) is a donor of acetyl groups and increases the intracellular levels of carnitine, the primary transporter of fatty acids across the mitochondrial membranes. In vivo studies showed that ALCAR decrease oxidative stress markers and pro-inflammatory cytokines. In a previous double-blind placebo-controlled phase II trial showed positive effects on self-sufficiency (defined as a score of 3+&#x2009;on the ALSFRS-R items for swallowing, cutting food and handling utensils, and walking) ALSFRS-R total score and FVC. We conducted an observational, retrospective, multicentre, case-control study to provide additional data on the effects of ALCAR in subjects with ALS in Italy. Subjects treated with ALCAR 1.5&#xa0;g/day or 3&#xa0;g/day were included and matched with not treated subjects by sex, age at diagnosis, site of onset, and time from diagnosis to baseline, (45 subjects per group). ALCAR 3&#xa0;g/day vs not treated: 22 not treated subjects (48.9%) were still alive at 24&#xa0;months after baseline, compared to 23 (51.1%) treated subjects (adj. OR 1.18, 95% CI 0.46-3.02). No statistically significant differences were detected in ALSFRS nor FVC nor self-sufficiency. ALCAR 1.5&#xa0;g/day vs not treated: 22 not treated subjects (48.9%) were still alive at 24&#xa0;months after baseline, compared to 32 (71.1%) treated subjects (adj. OR 0.27, 95% CI 0.10-0.71). For ALSFRS-R, a mean slope of -&#x2009;1.0 was observed in treated subjects compared to -&#x2009;1.4 in those not treated (p&#x2009;=&#x2009;0.0575). No statistically significant difference was detected in the FVC nor self-sufficiency. Additional evidence should be provided to confirm the efficacy of the drug and provide a rationale for the dosage.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Sassi</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bianchi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamanti</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Neuro-Oncology Unit, IRCCS Mondino Foundation, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tornabene</LastName><ForeName>Danilo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neuro-Oncology Unit, IRCCS Mondino Foundation, Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sette</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>UO di Neurologia Dipartimento Neuroscienze e Riabilitazione, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medici</LastName><ForeName>Doriana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Presidio Ospedaliero Fidenza AUSL Parma, Fidenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mat&#xe0;</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Dipartimento Neuromuscoloscheletrico e Degli Organi di Senso, Azienda Ospedaliero-Universitaria di Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leccese</LastName><ForeName>Deborah</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Dipartimento Neuromuscoloscheletrico e Degli Organi di Senso, Azienda Ospedaliero-Universitaria di Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sperti</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento Neuromuscoloscheletrico e Degli Organi di Senso, Azienda Ospedaliero-Universitaria di Careggi, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinelli</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghezzi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, Centre for Neuroscience and Nanotechnology, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iuzzolino</LastName><ForeName>Valentina Virginia</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubbioso</LastName><ForeName>Raffaele</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trojsi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche e Chirurgiche Avanzate, Universit&#xe0; degli Studi della Campania "Luigi Vanvitelli", P.Zza Miraglia 2, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passaniti</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche e Chirurgiche Avanzate, Universit&#xe0; degli Studi della Campania "Luigi Vanvitelli", P.Zza Miraglia 2, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Alvano</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche e Chirurgiche Avanzate, Universit&#xe0; degli Studi della Campania "Luigi Vanvitelli", P.Zza Miraglia 2, Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filosto</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, NeMO-Brescia Clinical Center for Neuromuscular Diseases, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padovani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, Unit of Neurology ASST Spedali Civili Di Brescia, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazzini</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ALS Center Azienda Ospedaliero Universitaria "Maggiore della Carit&#xe0;" e Universit&#xe0; del Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Center Azienda Ospedaliero Universitaria "Maggiore della Carit&#xe0;" e Universit&#xe0; del Piemonte Orientale, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinno</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuredini</LastName><ForeName>Andi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine and Surgery, University of Parma, Parma, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bongioanni</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dpt. Medical Specialties, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolciotti</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dpt. Medical Specialties, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canali</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>U.O di Neurologia, Presidio Ospedaliero S.Maria Nuova Azienda USL, IRCCS di Reggio Emilia, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toschi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>U.O di Neurologia, Presidio Ospedaliero S.Maria Nuova Azienda USL, IRCCS di Reggio Emilia, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petrucci</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neuromuscular and Neurological Rare Diseases, San Camillo Forlanini Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perna</LastName><ForeName>Alessia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Neuromuscular and Neurological Rare Diseases, San Camillo Forlanini Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riso</LastName><ForeName>Vittorio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Center for Neuromuscular and Neurological Rare Diseases, San Camillo Forlanini Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inghilleri</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze Umane, Universit&#xe0; di Roma "Sapienza" UOSD Malattie Neurodegenerative-Centro Malattie Rare Neuromuscolari, Policlinico Universitario Umberto I, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Libonati</LastName><ForeName>Laura</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4323-3598</Identifier><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze Umane, Universit&#xe0; di Roma "Sapienza" UOSD Malattie Neurodegenerative-Centro Malattie Rare Neuromuscolari, Policlinico Universitario Umberto I, Rome, Italy. laura.libonati@uniroma1.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cambieri</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dipartimento di Neuroscienze Umane, Universit&#xe0; di Roma "Sapienza" UOSD Malattie Neurodegenerative-Centro Malattie Rare Neuromuscolari, Policlinico Universitario Umberto I, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pupillo</LastName><ForeName>Elisabetta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>6DH1W9VH8Q</RegistryNumber><NameOfSubstance UI="D000108">Acetylcarnitine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurol. 2023 Sep 8;:</RefSource><PMID Version="1">37682317</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000108" MajorTopicYN="Y">Acetylcarnitine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Case&#x2013;control</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Neurological disease</Keyword><Keyword MajorTopicYN="N">Observational study</Keyword><Keyword MajorTopicYN="N">Treatment</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>13</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>28</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37378756</ArticleId><ArticleId IdType="pmc">PMC10576701</ArticleId><ArticleId IdType="doi">10.1007/s00415-023-11844-6</ArticleId><ArticleId IdType="pii">10.1007/s00415-023-11844-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feldman EL, Goutman SA, Petri S, Mazzini L, Savelieff MG, Shaw PJ, Sobue G. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363&#x2013;1380. doi: 10.1016/S0140-6736(22)01272-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01272-7</ArticleId><ArticleId IdType="pmc">PMC10089700</ArticleId><ArticleId IdType="pubmed">36116464</ArticleId></ArticleIdList></Reference><Reference><Citation>Virmani A, Binienda Z. Role of carnitine esters in brain neuropathology. Mol Aspects Med. 2004;25(5&#x2013;6):533&#x2013;549. doi: 10.1016/j.mam.2004.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2004.06.003</ArticleId><ArticleId IdType="pubmed">15363640</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigini P, Larini S, Pasquali C, Muzio V, Mennini T. Acetyl-l-carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neurosci Lett. 2002;329(3):334&#x2013;338. doi: 10.1016/s0304-3940(02)00667-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0304-3940(02)00667-5</ArticleId><ArticleId IdType="pubmed">12183043</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigini P, Muzio V, de Angelis C, Mennini T. In vitro and in vivo effect of acetyl-l-carnitine on motor neuron degeneration. Neurosci Lett. 1999;52:S18.</Citation></Reference><Reference><Citation>Li X, Zhang C, Zhang X, et al. An acetyl-l-carnitine switch on mitochondrial dysfunction and rescue in the metabolomics study on aluminium oxide nanoparticles. Part Fibre Toxicol. 2015;13:4. doi: 10.1186/s12989-016-0115-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12989-016-0115-y</ArticleId><ArticleId IdType="pmc">PMC4715336</ArticleId><ArticleId IdType="pubmed">26772537</ArticleId></ArticleIdList></Reference><Reference><Citation>Kocsis K, Frank R, Szab&#xf3; J, Knapp L, Kis Z, Farkas T, V&#xe9;csei L, Toldi J. Acetyl-l-carnitine restores synaptic transmission and enhances the inducibility of stable LTP after oxygen-glucose deprivation. Neuroscience. 2016;22(332):203&#x2013;211. doi: 10.1016/j.neuroscience.2016.06.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2016.06.046</ArticleId><ArticleId IdType="pubmed">27378558</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazak F, Yarim GF. Neuroprotective effects of acetyl-l-carnitine on lipopolysaccharide-induced neuroinflammation in mice: involvement of brain-derived neurotrophic factor. Neurosci Lett. 2017;29(658):32&#x2013;36. doi: 10.1016/j.neulet.2017.07.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2017.07.059</ArticleId><ArticleId IdType="pubmed">28822835</ArticleId></ArticleIdList></Reference><Reference><Citation>Altun Z, Olgun Y, Ercetin P, Aktas S, Kirkim G, Serbetcioglu B, Olgun N, Guneri EA. Protective effect of acetyl-l-carnitine against cisplatin ototoxicity: role of apoptosis-related genes and pro-inflammatory cytokines. Cell Prolif. 2014;47(1):72&#x2013;80. doi: 10.1111/cpr.12080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpr.12080</ArticleId><ArticleId IdType="pmc">PMC6496695</ArticleId><ArticleId IdType="pubmed">24286513</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Zeng X, Li L, Ou ZL. Carnitine promotes recovery from oxidative stress and extends lifespan in C. elegans. Aging (Albany NY). 2020;13(1):813&#x2013;830. doi: 10.18632/aging.202187.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.202187</ArticleId><ArticleId IdType="pmc">PMC7835055</ArticleId><ArticleId IdType="pubmed">33290254</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Bianchi E, Pupillo E, Lunetta C, Tremolizzo L, Logroscino G, Chi&#xf2; A, Preux PM, Beghi E. Non-self-sufficiency as a primary outcome measure in ALS trials. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17(1&#x2013;2):77&#x2013;84. doi: 10.3109/21678421.2015.1074704.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1074704</ArticleId><ArticleId IdType="pubmed">26470831</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:397&#x2013;405. doi: 10.3109/21678421.2013.764568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.764568</ArticleId><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B. 2000: Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265&#x2013;267. doi: 10.1212/01.wnl.0000194316.91908.8a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId><ArticleId IdType="pubmed">16434671</ArticleId></ArticleIdList></Reference><Reference><Citation>Herzmann C, Whiting SJ, Thomas M, Byrne P, Johnson MA, Youle M. Pharmacokinetics of acetyl-l-carnitine given in single or multiple doses to HIV-1 Infected patients with toxic peripheral polyneuropathy. Open AIDS J. 2008;2:39&#x2013;42. doi: 10.2174/1874613600802010039.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874613600802010039</ArticleId><ArticleId IdType="pmc">PMC2556204</ArticleId><ArticleId IdType="pubmed">18923701</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>